Real-time Estimate
Cboe BZX
14:34:03 2024-06-04 EDT
5-day change
1st Jan Change
48.6
USD
-0.51%
+5.60%
+5.14%
Presentation Operator MessageOperator (Operator)Hello, and thank you for joining us to discuss...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
05-14
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024
05-14
CI
Belite Bio's Q1 Loss Narrows
05-14
MT
Transcript : Belite Bio, Inc - Special Call
05-13
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
05-06
CI
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares
04-26
MT
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan
03-22
MT
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
03-22
CI
ADRs End Higher, ATRenew Inc. Climbs 26.9%
03-12
DJ
Transcript : Belite Bio, Inc, Q4 2023 Earnings Call, Mar 12, 2024
03-12
Belite Bio's Q4 Loss Narrows
03-12
MT
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023
03-12
CI
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-12
CI
Belite Bio Gets Clearance to Launch Tinlarebant Phase 3 Trial for Eye Disease in China
12-27
MT
Maxim Starts Coverage on Belite Bio with Buy Rating, $60 Price Target
12-14
MT
Transcript : Belite Bio, Inc, Q3 2023 Earnings Call, Nov 14, 2023
11-14
Belite Bio, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
Belite Bio's Q3 Loss Widens
11-14
MT
Transcript : Belite Bio, Inc Presents at DbVIC - Deutsche Bank Depositary Receipts Virtual Investor Conference, Nov-08-2023 11:00 AM
11-08
HC Wainwright Raises Price Target on Belite Bio to $59 From $55, Maintains Buy Rating
11-06
MT
Belite Bio, Inc. Presents Results from a 24-Month, Phase 2 Study of Tinlarebant in Childhood-Onset Stargardt Disease at the AAO Annual Meeting
11-06
CI
ADRs Dip; Voxeljet AG Declines 24%
23-08-18
DJ
Transcript : Belite Bio, Inc, Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Belite Bio, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Cantor Fitzgerald Initiates Belite Bio at Overweight Rating With $43 Price Target
23-07-28
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
More about the company
Last Close Price
48.85
USD
Average target price
56.5
USD
Spread / Average Target
+15.66%
Consensus
1st Jan change
Capi.
+5.14% 1.46B +45.90% 56.65B -6.79% 39.44B +39.19% 39.03B -6.65% 26.86B +12.64% 26.75B -21.23% 19.03B +0.91% 12.28B +24.13% 12.26B +27.29% 12.04B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1